Connecting Global Innovation to China's Life Science & MedTech Market

MTL works with international manufacturers of life science instruments, laboratory equipment, and medical devices looking to enter or expand in the Chinese market. Ideal partners are companies with validated products seeking an established, authorized channel to China's hospitals, universities, research institutes, and industrial laboratories — at any stage from initial market exploration to active distribution scale-up.

The NMPA (National Medical Products Administration) governs the registration and approval of medical devices in China. The process involves product classification, preparation of technical documentation, clinical evaluation or clinical trial coordination, and formal submission to NMPA. Manufacturing license applications run in parallel where required. MTL guides international clients through every step — from initial regulatory pathway assessment to final approval — working alongside established local regulatory affairs specialists.

CDMO (Contract Development and Manufacturing Organization) is a strategic partnership that allows international medical device companies to manufacture products using pre-qualified facilities in China, without the capital burden of building their own factory. This approach significantly accelerates market entry while ensuring full regulatory compliance.

How CDMO Works:

1. Partner Selection — MTL identifies suitable Chinese CDMO partners based on your product specifications, manufacturing capacity, certifications, and compliance history.
2. Contractual Arrangement — We negotiate and establish manufacturing agreements compliant with Chinese law, IP protection, and quality standards.
3. NMPA License Application — MTL guides the application for China manufacturing licenses and supports regulatory documentation throughout the process.
4. Quality Oversight — Ongoing production monitoring, process validation, and regulatory compliance verification.

Key Benefits: Reduced capital expenditure, access to pre-certified manufacturers, faster time-to-market (6-12 months vs 18-24 months for new facilities), and guaranteed regulatory compliance.

Typical Cost Range: $50K–$200K for contract setup and license facilitation, depending on product complexity and regulatory classification.

Yes. MTL maintains a network of pre-qualified, China GLP-accredited laboratories covering both pharmaceutical and medical device testing standards.

Pharmaceutical GLP Services: Pre-clinical studies for drug candidates, biologics, and therapeutic agents. Includes toxicology, pharmacokinetics (PK), pharmacodynamics (PD), and safety assessment studies conducted to NMPA and international GLP standards.

Medical Device GLP Services: Biocompatibility testing (ISO 10993), toxicology studies, material safety evaluations, device performance testing, and sterility/endotoxin validation. All reports meet China NMPA regulatory requirements for medical device registration.

Key Advantage: GLP reports generated by our partner laboratories are formatted to meet both China NMPA requirements AND international regulatory standards (US FDA, EU MDR, etc.), providing significant dual-market value. This accelerates global regulatory approvals while establishing China market credentials.

Typical Turnaround: 8-16 weeks, depending on study scope and complexity.

Geographic Coverage: MTL's distribution network spans all 31 provinces of China, including coverage in tier-1 (Beijing, Shanghai, Guangzhou, Shenzhen), tier-2, and tier-3 cities. We maintain relationships across:

• Public and private hospitals (2,000+ facilities)
• University research institutes and life science centers
• Government laboratories and regulatory bodies (NMPA testing centers, CDC)
• Industrial facilities, high-tech parks, and contract manufacturers
• Regional distributors and specialized equipment suppliers

Commercial Services: Beyond distribution placement, MTL provides Key Opinion Leader (KOL) engagement for thought leadership and product adoption, government procurement channel navigation, tradeshow and exhibition support, and localized training and customer support.

Market Intelligence: We gather real-time competitive and purchasing pattern data across regions, enabling data-driven pricing, marketing, and promotional strategies tailored to regional demand.

Result: Comprehensive commercial coverage for both life science tools and medical devices, ensuring your products reach end-users across China's entire healthcare and research ecosystem.

Getting Started — 3 Simple Steps:

1. Submit Your Inquiry — Use the contact form on this page. Tell us about your product category (life science tools vs medical device), regulatory status, and initial goals (market entry, distribution, NMPA support, or CDMO facilitation).
2. Introductory Consultation — Our team will schedule a 30-minute call to understand your product specifications, current China market presence (if any), regulatory timeline, and commercial targets.
3. Customized Engagement Proposal — We'll propose a tailored service package covering the highest-priority items: which services to engage, timeline expectations, cost structure, and success metrics.

What We'll Cover: Your product's regulatory classification in China, NMPA registration pathway and timeline, suitable CDMO partners (if applicable), GLP testing requirements, market entry strategy, pricing and distribution channels, and ongoing support structure.

Our Flexibility: We work with companies at every stage — from initial China market exploration and feasibility assessment, to active distribution partnerships, to large-scale CDMO or GLP project launches. Most engagements begin with focused support on your most urgent priority, then expand as commercial momentum builds.

Typical Response Time: We respond to inquiries within one business day.